Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition

Abstract

Clinical practice guidelines for gynecologic cancers have been published by the National Comprehensive Cancer Network and the National Cancer Institute. Whereas these guidelines form the basis for the standard of care for gynecologic malignancies in the United States, it has proven difficult to institute them in Japan due to differences in patient characteristics, health-care delivery systems, and insurance programs. Therefore, evidence-based guidelines for treating cervical cancer specifically in Japan have been under development. The Guidelines Formulation Committee and Evaluation Committee were independently established within the Committee for Treatment Guidelines for Cervical Cancer. Opinions from within and outside the Japan Society of Gynecologic Oncology (JSGO) were incorporated into the final draft, and the guidelines were published after approval by the JSGO. These guidelines are composed of ten chapters and comprise three algorithms. Each chapter consists of a clinical question, recommendations, background, objectives, explanations, and references. The objective of these guidelines is to clearly delineate the standard of care for cervical cancer treatment in Japan in order to ensure equitable care for all Japanese women diagnosed with cervical cancer.

ATL: Results of a Multi-Institutional Phase 2 Study (JGOG1066)

“…1 However, the Japanese treatment guideline for cervical cancer published in 2007 gave CCRT a grade B recommendation. 2 The guideline stated that clinical questions remained to be answered before CCRT could be designated as a standard therapy with a grade A recommendation in Japan. 2 The Gynecologic Oncology Group (GOG) protocol 120 demonstrated that a weekly dose of 40 mg/m 2 of intravenous cisplatin for 6 weeks was equally efficacious and less toxic compared with a combination regimen of cisplatin and 5-fluorouracil for 2 cycles of CCRT.…”

Questionnaire survey of the current status of radical trachelectomy in Japan

“…The recommended surgical treatment for women with stage Ib2-Ib1 cervical cancer is a radical hysterectomy and bilateral pelvic lymphadenectomy [9]; however, many women diagnosed with cervical cancer have not completed their childbearing. There is increasing evidence in the literature that radical trachelectomy is a viable option for young women with cervical cancer who wish to preserve their fertility [10,11]; however, the eligibility for this procedure is controversial.…”

Patterns of cervical cancer care in Argentina: Applying ASCO recommendations adjusted by local resources

“…If residual disease persists 2 months after radiotherapy, extrafascial hysterectomy can be a valid option. (Chuang et al, 2016, Nagase et al, 2010, Cetina et al, 2013, Kokka et al, 2015, Censo Nacional de Población, 2010). …”